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Summary
Pten−/− cells display a partially defective checkpoint in response to ionizing radiation (IR). The checkpoint defect was
traced to the ability of AKT to phosphorylate CHK1 at serine 280, since a nonphosphorylated mutant of CHK1 (S280A)
complemented the checkpoint defect and restored CDC25A degradation. CHK1 phosphorylation at serine 280 led to cova-
lent binding of 1 to 2 molecules of ubiquitin and cytoplasmic CHK1 localization. Primary breast carcinomas lacking PTEN
expression and having elevated AKT phosphorylation had increased cytoplasmic CHK1 and displayed aneuploidy (p <
0.005). We conclude that loss of PTEN and subsequent activation of AKT impair CHK1 through phosphorylation, ubiquitina-
tion, and reduced nuclear localization to promote genomic instability in tumor cells.S I G N I F I C A N C E
Upregulation of the PI-3 kinase pathway—whether through inactivation of PTEN or activation of PI-3 kinase and AKT—is frequently
observed in human solid tumors. In mice, mutation of PTEN stimulates AKT kinase in normal cells but is not sufficient to induce
tumorigenesis. Nevertheless, cells lacking PTEN have an enhanced capacity to evolve into tumors. Here we demonstrate that CHK1,
a critical regulator of chromosomal stability, is impaired in cells lacking PTEN due to AKT-mediated phosphorylation at serine 280,
which triggers ubiquitination and cytoplasmic sequestration. ATM kinase therefore has access to a smaller pool of nuclear CHK1 to
initiate the DNA damage checkpoint. This impairment of CHK1 function contributes to the rapid rate at which PTEN mutant cells
evolve into tumors.Introduction
Impairment of DNA damage checkpoint pathways is closely
linked to cellular transformation (Elledge, 1996). Inherited mu-
tations in the DNA damage checkpoint genes ATM, p53,
CHK2, and BRCA1 are associated with a predisposition to ma-
lignancy in humans (Bell et al., 1999; Cortez et al., 1999; Kas-
tan et al., 1992; Malkin et al., 1990; Savitsky et al., 1995; Tib-
betts et al., 2000). These genes protect the body from
neoplasia by preventing genetic damage from being passed
onto daughter cells. Depending upon the type of DNA damage,
ATM or ATR kinase is required for initiation of the checkpoint
response (Canman et al., 1998; Wright et al., 1998). ATM and
ATR kinase phosphorylate a variety of substrates, including
BRCA1, p53, CHK1, and CHK2 (Guo et al., 2000; Siliciano et
al., 1997; Tibbetts et al., 2000). DNA damage activates the
CHK1 protein and leads to a marked increase in the phosphor-
ylation and destruction of CDC25A. As a result, cyclin/cdk
complexes remain phosphorylated in an inactive state, and
cells undergo a transient arrest in the G1, S, and G2 phases ofCANCER CELL : FEBRUARY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIERthe cell cycle (Mailand et al., 2000; Sorensen et al., 2003; Zhao
et al., 2002).
In addition to the role of CHK1 in checkpoint activation, it
participates in the control of the normal cell cycle, in part
through the regulation of Cdc25A (Chen et al., 2003; Sorensen
et al., 2003; Zhao et al., 2002). Reduction of CHK1 with RNAi
in human cells results in increased CDC25A (Sorensen et al.,
2003; Zhao et al., 2002). In some cells, CHK1 protein and its
kinase levels are low in resting cells, increase in G1 and S
phase, and fall in late G2/M (Kaneko et al., 1999). Conditional
biallelic inactivation of chk1 in mouse embryonic stem cells
leads to numerical and structural chromosomal aberrations
and apoptosis after only a few cell divisions (Liu et al., 2000;
Takai et al., 2000). Therefore, CHK1 has a critical role in main-
taining genomic stability in a normal cell cycle.
PTEN, a potent tumor suppressor, is inactivated in a large
proportion of human tumors (Li et al., 1997; Steck et al., 1997).
Inactivation of PTEN leads to increased levels of the phospho-
lipid phosphatidylinositol-3,4,5-trisphosphate, which activates
the PI-3 kinase signaling cascade (Maehama and Dixon, 1998;INC. DOI 10.1016/j.ccr.2005.01.009 193
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inactivation of PTEN in normal cells links it to the regulation of
cell characteristics such as size, apoptosis, and proliferation
status (Kishimoto et al., 2003). Aberrations in enzymatic signal-
ing due to PTEN loss include activation of AKT kinase (protein
kinase B) and p70 S6 kinase (Cantley and Neel, 1999; Lu et al.,
1999). Cells lacking PTEN therefore have persistent phosphor-
ylation of AKT substrates such as GSK3β, FOXO1, p27,
MDM2, TSC2, and BAD, and S6K substrates such as ribo-
somal subunit S6 (Wishart and Dixon, 2002). Inactivation of
PTEN is by itself insufficient to cause cellular transformation;
however, over a brief period of time, a subset of cells lacking
PTEN evolve into tumors (Sulis and Parsons, 2003). It has been
observed in a small cohort of breast carcinomas that PTEN-
deficient tumors tend to be aneuploid (Bose et al., 2002); there-
fore, it is possible that lack of PTEN stimulates genetic instabil-
ity. This idea is supported by the observation that PTEN-defi-
cient cells have attenuated function of p53, a critical check-
point protein (Mayo et al., 2001; Zhou et al., 2001).
Several lines of evidence suggest a role for PTEN and the
PI-3 kinase pathway in the regulation of CHK1. During the cell
cycle, AKT kinase activity rises in G2/M, which is coincidental
with the fall in CHK1 kinase activity (Shtivelman et al., 2002).
Inhibition of the PI-3 kinase pathway with PTEN or a PI-3 ki-
nase inhibitor leads to cell cycle arrest in G2 phase (Kandel et
al., 2002; Saito et al., 2003; Shtivelman et al., 2002). Such inhi-
bition is relieved by overexpression of constitutively active AKT
kinase. Importantly, AKT inhibits CHK1 kinase activity, whereas
PI-3 kinase inhibitor LY294002 enhances its kinase activity
(Shtivelman et al., 2002). Review of the literature also supports
the notion that the PI-3 kinase-PTEN-AKT pathway regulates
CHK1-dependent checkpoint activation. A PI-3 kinase inhibitor
shortens the IR-induced G2 arrest (Blasina et al., 1999),
whereas constitutively active AKT blocks hydroxyurea-induced
activation of chk1 and DNA damage-induced arrest in G2 (Shti-
velman et al., 2002). The ability of AKT to regulate CHK1 poten-
tially occurs through a consensus AKT phosphorylation site at
amino acid 280 of CHK1, which AKT is capable of phosphory-
lating in vitro and in vivo (King et al., 2004). Thus, the existing
literature argues in favor of AKT regulating CHK1 function. In
this report, we demonstrate that CHK1 nuclear localization is
attenuated through phosphorylation and ubiquitination in
PTEN-deficient cells, which leads to abnormal checkpoint con-
trol and genetic instability.
Results
Generation of Pten−/− embryonic stem cells
Mouse embryonic stem (MES) cells rely upon chk1 and chk2
to mediate the G2 checkpoint activated by IR (Hirao et al.,
2000; Liu et al., 2000; Takai et al., 2000). To investigate the role
of the PTEN tumor suppressor in checkpoint regulation, we
generated a series of Pten −/− (null) MES cell clones by mutat-
ing both Pten alleles with neomycin and hygromycin targeting
constructs (Figure 1A) (Podsypanina et al., 1999). The mu-
tations were designed to inactivate Pten by deleting the phos-
phatase domain. Multiple Pten−/− clones were identified (Figure
1B) and confirmed for their diploid karyotypic status (data not
shown). Pten−/− clones expressed no detectable Pten protein
(Figures 1C and 1D). Such cells had enhanced Akt phosphory-
lation and kinase activity as measured by immunoblot with an-194Figure 1. Generation of murine Pten knockout embryonic stem cells
A: A map of the genomic Pten locus and the two constructs used to disrupt
it. Correct targeting results in the deletion of the indicated fragment lo-
cated in between two Bgl II restriction sites by a hygromycin resistance
cassette in one allele and a neomycin in the other.
B: Southern blot analysis of the isolated clones using Probe A. Genomic
DNA was digested with PstI. Pten+/− wild-type (WT), +/− (Het), and −/− (Null)
clones are shown.
C: Western blotting of a wild-type, a heterozygous, and a representative
nullizygous ES clone. The heterozygous clone expresses a lower amount of
the Pten protein than does the wild-type clone.
D: Analysis of phospho-Akt (S473) and phospho-Gsk3 (serines 21 and 9) in
the wild-type and the representative nullizygous clone. Pten null cells have
a high basal level of phosphorylated Akt and glycogen synthase kinase 3.tibodies that detected phospho-serine-473 of Akt and its phos-
phorylated substrates Gsk3-α and -β when compared to Pten+/
+ MES cell (Figures 1C and 1D). Clones of all three genotypes
(Pten+/+, +/−, and −/−) proliferated at similar rates when grown
in the presence of 15% fetal bovine serum and leukemia inhibi-
tory factor on feeder cells (data not shown).
Checkpoint defects in Pten−/− cells
To examine the ability of the cells to respond to IR exposure,
cells were treated with 10 Gy. We consistently noticed that
Pten−/− cells did not arrest in G2 as efficiently as Pten+/+ cells
(Figure 2A). Moreover, 24 hr after radiation exposure, approxi-
mately half of the bromodeoxyuridine-labeled Pten−/− cells had
entered G1 phase, while the labeled Pten+/+ cells were pre-
dominantly arrested in G2. To determine whether the early re-
sponse to IR was affected as well, MES cells were irradiated
and examined for their mitotic indices 1 and 2 hr later. Pten−/−
cells failed to efficiently induce the early checkpoint at both
time points (Figure 2B). This result was verified when meta-
phases were counted 30, 60, and 90 min post-IR exposure of
1 Gy (Figure 2C). Chromosome examination revealed that
Pten−/− cells prematurely exited from G2 phase after IR treat-
ment, as is evident from mitotic index as well as higher fre-
quency of chromatid gaps and breaks observed in Pten−/− cells
(Figure 2D).
Phosphorylation of chk1 serine 280 is regulated
by Akt and Pten
To determine whether phosphorylation of chk1 occurs in vivo,
an affinity purified anti-chk1 phosphoserine 280 antibody wasCANCER CELL : FEBRUARY 2005
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Pten−/− cells
A: Defect of cell cycle response to γ radiation
in Pten−/− cells. S phase cells were pulsed with
bromodeoxyuridine (BrdU, marked yellow) and
then exposed to 10 Gy of ionizing radiation. To-
tal DNA was stained with propidium iodide
(marked blue). Histograms show superimposed
images.
B and C: Rapid G2 checkpoint is defective in
Pten−/− cells. B: Cells were irradiated with 10 Gy
of γ radiation and costained with phospho-his-
tone H3 (S10) antibody and propidium iodide.
C: ES cells were treated with 1 Gy of γ rays. Cells
were harvested 30, 60, and 90 min later and ex-
amined for mitoses. p < 0.01 at 60 min.
D: Pten null cells enter mitosis with unrepaired
chromosomes. Giemsa-stained chromosomes
from metaphases were analyzed for double-
stranded gaps and breaks 0, 45, and 90 min af-
ter treatment with 1 Gy of ionizing radiation.
Four different Pten−/− clones have been deter-
mined to have checkpoint defects in response
to ionizing radiation. Error bars represent the
standard deviation of the mean of three inde-
pendent experiments in which 100 cells were
counted.generated. To test whether the antibody was able to specifi-
cally detect phosphorylation of S280 by immunoblot, Chk1
was knocked down in mouse fibroblasts with a short hairpin
RNAi retroviral construct that targeted Chk1. Downregulation
of total protein expression led to diminution of the phospho-
specific band as well (Figure 3A, upper panel). In addition,
treatment of cell extracts from Pten−/− cells with calf intestinal
alkaline phosphatase led to a considerable reduction in detect-
able phosphoprotein in the phosphatase-treated lane (Figure
3A, lower panel). Analysis of the same immunoblot with a mo-
noclonal antibody to chk1 demonstrated that chk1 protein was
present in the same lane. In order to examine the ability of myr-
AKT to phosphorylate chk1, we cotransfected HEK293 cells
with either wild-type chk1 or chk1S280A (a mutant of chk1 in
which the serine at 280 has been substituted with an alanine).
AKT stimulated chk1 serine 280 phosphorylation of wild-type
chk1 but not of the chk1S280A mutant (Figure 3B).
To test whether growth factors stimulate phosphorylation of
chk1 on serine 280 in a PI-3 kinase-dependent manner,
HEK293 cells were transfected with wild-type mouse chk1 and
serum starved for 24 hr prior to stimulation with IGF1 in the
presence or absence of inhibitors. As expected, IGF1 stim-
ulated AKT and ERK phosphorylation, and PI-3 kinase inhibi-
tors blocked AKT activation and partially impaired ERK phos-
phorylation. IGF1 stimulated chk1 phosphorylation on serine
280 (Figure 3C). Inhibition of PI-3 kinase with either wortmannin
or LY294002 blocked induction of phosphorylation at the ser-
ine 280, but inhibition with rapamycin did not. The MEK inhibi-
tor PD98059 inhibited IGF1-induced activation of the pathwayCANCER CELL : FEBRUARY 2005but not to the same extent as the PI-3 kinase inhibitors in a
setting of complete inactivation of ERK phosphorylation. Ex-
amination of NIH/3T3 cells for the ability to phosphorylate en-
dogenous chk1 in response to growth factor stimulation
showed that stimulation with either IGF1 or insulin led to induc-
tion of a band with the phospho-serine 280 antibody (Figure
3D). This signal was repressed when either ligand was added
to cells in the presence of wortmannin. The aforementioned
data demonstrate that the PI-3 kinase is able to stimulate
phosphorylation of chk1 serine 280. To determine whether Pten
regulates phosphorylatation of chk1 serine 280, the phosphos-
pecific antibody to chk1 serine 280 was used to immunopreci-
pitate chk1 in Pten+/+ and Pten−/− MES cells. Unstimulated
Pten−/− MES cells contained detectable phosphoserine-280
chk1, while Pten+/+ cells did not (Figure 3E).
Serine 280 is an important regulator
of CHK1 cellular localization
As demonstrated above, AKT kinase effectively phosphorylates
chk1-S280 in vivo. To determine whether chk1-S280 is respon-
sible for the checkpoint defect seen in Pten−/− MES cells, wild-
type, S280A, and S280E chk1 were expressed in Pten−/− ES
cells, irradiated, and treated with nocodazole. At 24 hr post-
treatment, both wild-type and chk1S280A rescued the pheno-
type. No rescue was seen with the phosphomimetic chk1S280E
construct. Surprisingly, chk1S280A decreased the number of mi-
totic cells even below the level seen in the wild-type counter-
parts (Figure 4A). This would argue that the chk1S280A mutant
protein is more potent in activating the checkpoint than the195
A R T I C L EFigure 3. Phosphorylation of chk1 at serine 280
A: Reactivity of Chk1 phospho-specific antibody (S280). Upper panel: chk1
was knocked down by shRNAi in MEFs. Cell lysates were resolved by SDS-
PAGE and the membrane was probed for pS280-Chk1. The same mem-
brane was stripped and reprobed for total Chk1. Lower panel: protein ex-
tracts from Pten nullizygous MES cells were treated with calf intestinal phos-
phatase in the presence or absence of phosphatase inhibitors and
analyzed by Western blotting. Phosphatase treatment of protein extracts
affects the ability of the antibody to recognize the phosphorylated
epitope.
B: AKT phosphorylates chk1 at serine 280. pChk1(S280) antibody recognizes
the wild-type but not mutant (S280A) mouse protein in a cotransfection
experiment with myristoylated AKT in HEK293 cells. Cells were cotrans-
fected with either wild-type or S280A chk1 constructs and myrAKT. Lysates
were resolved by SDS-PAGE and transferred to PVDF membranes prior to
incubation with the indicated antibodies.
C: Phosphorylation of S280 is dependent on IGF I-induced activation of PI-
3K/AKT signaling. HEK293 cells were transfected with mouse Chk1 and
starved for 24 hr in serum-free media. Wortmannin (100 nM) was added 15
min prior to mitogen addition. LY 294002 (10 M), rapamycin (200 nM),
and PD980059 (50 M) were added 2 hr prior to IGF I addition. Cells were
stimulated with IGF I (100 ng/ml) for 15 min, lysed, and analyzed by Western
blot with the indicated antibodies.
D: Phosphorylation of endogenous chk1 in NIH/3T3 cells is growth factor-
dependent and requires PI-3 kinase. Cells were starved for 24 in serum-free
DMEM, preincubated with 100 nM wortmannin for 15 min, and treated with
insulin (100 ng/ml) or IGF I (100 ng/ml) for 15 min.
E: Increased levels of pS280-chk1 levels are present in PTEN−/− cells. Endog-
enous pChk1 was precipitated from MES cell lysates using phospho-spe-
cific anti-phosphoserine 280 antibody. Proteins were resolved by SDS-PAGE
and detected with Chk1 antibody.wild-type protein. To further investigate the effect of the muta-
tion, we considered the possibility that stability of the protein
might be affected. Therefore, U20S cells were transfected with
wild-type, S280A, and S280E CHK1 constructs. Protein syn-
thesis inhibitor cycloheximide was added to the media 24 hr
posttransfection. No difference in CHK1 protein levels was ob-
served up to 6 hr after addition of the inhibitor, arguing that196CHK1 activity was regulated by a mechanism other than half-
life. Additionally, there was no difference in in vitro kinase activ-
ity after immunoprecipitation of transfected untreated cell ly-
sates (data not shown).
Upon DNA damage, CHK1 protein has been shown to local-
ize to the nucleus, where it could be activated by ATM and ATR
kinases and initiate the checkpoint response (Jiang et al.,
2003). To determine whether subcellular localization of CHK1
could be altered due to activation of the PI-3K-AKT pathway,
CHK1 was expressed in U2OS cells and examined by indirect
immunofluorescence. Although primarily nuclear, a significant
amount of CHK1 was also detected in the cytoplasm of cells.
The nuclear-to-cytoplasmic ratio for wild-type CHK1 and the
S280A mutant was greater than for the S280E mutant (Figures
4B–4D). The S280E mutant exhibited a pancellular localization,
being present in both the nucleus and cytoplasm regardless of
radiation treatment. Thus, it appears likely that the defect of
chk1 seen in Pten−/− cells may be due to altered intracellular lo-
calization.
Altered signaling of chk1 due to S280 phosphorylation
Cytoplasmic localization of CHK1 would render it inaccessible
to activation by ATM/ATR in response to DNA damage. To test
the fidelity of the chk1 signal in Pten−/− cells, wild-type and
nullizygous ES cells were irradiated with 10 Gy and examined
for the induction of chk1 serine 345 phosphorylation. Pten−/−
cells failed to efficiently activate S345 phosphorylation as well
as wild-type, although the total levels of chk1 were similar be-
tween wild-type and Pten−/− (Figure 4E, upper left panel). One
of the major substrates of chk1 is cdc25A, which is rapidly
degraded upon phosphorylation (Sorensen et al., 2003; Zhao
et al., 2002). As expected in a setting of reduced chk1 function,
increased levels of cdc25A were observed in Pten−/− cells after
IR treatment at all time points (Figure 4E, upper left panel) (Mai-
land et al., 2000). Interestingly, expression of the S280A, but
not the S280E, Chk1 mutant in Pten nullizygous MES caused
reduction in the expression of cdc25A protein levels after radia-
tion treatment (Figure 4F), arguing that phosphorylation of
Chk1 on serine 280 contributes to the regulation of cdc25A
protein levels. In addition, these data are consistent with the
mitotic rescue seen with the S280A mutant-transfected PTEN
nulllizygous MES (Figure 4A). The CHK1 S280E mutation also
affected serine 345 phosphorylation after hydroxyurea treat-
ment of U2OS cells (Figure 4E, lower panel). Therefore, present
data suggest that altered cellular localization of chk1 reduces
its capacity to be phosphorylated at serine 345 and regulate
the cell cycle.
Endogenous AKT regulates the localization of CHK1
One question that is raised by the above results is, how does
AKT kinase access CHK1 in the nucleus? A recent study of AKT
function has determined that a subset of phosphorylated AKT
at serine 473 resides in the nucleus of endothelial cells (Adini
et al., 2003). To test the specificity of the phospho-serine 473
AKT antibody by immuofluorescence, wild-type and AKT1−/−
fibroblasts were stimulated with IGF I to activate the PI3K/AKT
axis. Clearly, staining was much brighter in the wild-type cells;
in particular, staining of the nucleus and membrane was pre-
sent in wild-type but not AKT1−/− fibroblasts (Supplemental
Figure S1). Dim cytoplasmic staining was seen in the mutant
cells, which may reflect AKT2 present in the cells. To validateCANCER CELL : FEBRUARY 2005
A R T I C L EFigure 4. Defective Chk1 signaling is due to ser-
ine 280 modification
A: Wild-type and S280A chk1 rescue IR-induced
phenotype of PTEN−/− cells. Pten−/− cells were
transfected with wild-type, S280A, and S280E
mouse Chk1, irradiated with 10 Gy of γ rays,
treated with nocodazole, and harvested at 24
hr. Cells were stained with phospho S10-Histone
H3 antibody and examined under fluorescent
light. * indicates p < 0.003 using student’s two-
tailed t test when compared to null.
B: Graph depicting the distribution of exoge-
nous CHK1 in U2OS cells. Here, at least 60 cells
were counted and evaluated by eye.
C and D: Expression of exogenous CHK1 in U2OS
cells showing nuclear localization of the S280A
mutant and cytoplasmic staining of the S280E
protein. Cells were cotransfected with myc-
tagged CHK1 and histone H2B-EGFP constructs.
18 hr after transfection, cells were irradiated
with 6 Gy of IR. 20 hr posttransfection, unirradi-
ated (C) and irradiated (D) cells were fixed
and stained.
E: Upper panel: Pten null MES cells are defective
in Chk1-responsive signaling. Cells were treated
with 10 Gy of ionizing radiation and harvested
at indicated times. Null cells display decreased
phosphorylation of S345-chk1 and increased ex-
pression of Cdc25A. Longer exposure of
Cdc25A blot shows that Cdc25A is not fully de-
graded at 30 min after radiation in Pten−/− cells.
Lower panel: CHK1 S280E is not phosphorylated
as well as wild-type on serine 345 after hy-
droxurea treatment. U2OS cells were trans-
fected with WT, S280E myc-tagged, and empty
pCDNA3 expression vectors. After 24 hr, 3 mM
hydroxyurea was added to cells for 17 hr. Ly-
sates were immunoblotted and probed with the
indicated antibodies.
F: Pten nullizygous cells were transfected with wild-type, S280A, or S280E mChk1 and assayed by Western for Cdc25A expression 1 hr after IR treatment.
S280A (denoted A) but not S280E (denoted E) mutant affects CDC25A protein levels in response to ionizing radiation.
Error bars represent the standard deviation of three independent experiments in which at least 400 cells were counted.the specificity of CHK1 monoclonal antibodies, siRNA for
CHK1 was transfected into U2OS cells. Reduced CHK1 signal
was evident in the cells transfected with siRNA specific to
CHK1, but not in cells transfected with control siRNA (Supple-
mental Figure S3).
Since it has been shown that during G2/M, AKT kinase levels
are highest when CHK1 kinase levels are lowest, we explored
the localization of endogenous chk1 and phosphoserine 473
AKT in synchronized U2-OS cells (Shtivelman et al., 2002) (Fig-
ure 5A). Cells were synchronized at the G1/S boundary with a
double thymidine block and released into fresh media. At 0 hr,
before the addition of fresh media, threonine 308 was phos-
phorylated, but serine 473 was barely detectable on AKT. At 1
hr after the addition of fresh media, phosphorylation at serine
473 was increased, which began to subside at 2 hr and was
followed by a wave of increased phosphorylation at 7 hr in late
G2 (Figure 5B) Using immunofluorescence of synchronized
cells, we determined that endogenous nuclear phosphoserine
473 of AKT could be detected in the nucleus throughout the
cell cycle, and that in late G2, an increase in both nuclear and
cytoplasmic AKT could be seen. The change in AKT intensity
at 7 hr and 8 hr correlated with a reduction in nuclear CHK1
staining that was apparent at 7 hr and 8 hr. Representative
images from 2 hr and 7 hr are shown (Figure 5C). These data
demonstrate that AKT has access to the CHK1 substrate inCANCER CELL : FEBRUARY 2005the nucleus and is most active when nuclear CHK1 levels are
decreasing. Loss of CHK1 from the nucleus in G2 may explain
why Cdc25A levels rise in G2/M of a cell cycle (Bernardi et
al., 2000).
To determine whether loss of PTEN and activation of AKT
resulted in exclusion of endogenous CHK1 protein from the
nuclear compartment, expression of PTEN in U2OS cells was
reduced by means of RNA interference with a retroviral shRNA
vector for PTEN. Pooled infected cells were larger and showed
reduced expression of PTEN and increased reactivity with pho-
spho S473-AKT antibody when compared to hairpin control
cells (Figure 5D). When examined by indirect immunocytofluor-
escence, many of the cells infected with PTEN shRNA dis-
played increased staining for phosphorylated AKT with numer-
ous nuclear foci (>20). Simultaneous examination of CHK1
showed that cells with nuclear phosphoS473-AKT had cyto-
solic CHK1 (Figure 5D). This phenomenon was observed only
rarely in the control hairpin cells.
To test the hypothesis that inhibition of AKT could result in
retention of CHK1 in the nucleus, cells were transfected with
short interfering RNAs to AKT and confirmed by immunoblot
(Supplemental Figure S2). As expected, the CHK1 signal was
exclusively nuclear, demonstrating that downregulation of the
AKT kinase levels resulted in nuclear compartmentalization of197
A R T I C L EFigure 5. PI3-K/AKT pathway regulates localization of endogenous CHK1
A–C: Analysis of endogenous pAKT and endogenous CHK1 in synchronized U2OS cells. A: Flow cytometry profile of synchronized cells at indicated times
after release from thymidine block. B: Biphasic increased AKT kinase activity as demonstrated by phosphorylated Thr 308 and Ser 473. C: Nuclear AKT
phosphoserine 473 is declining in early S phase cells (2 hr time point) and is coincidental with nuclear CHK1 staining pattern, whereas it is increasing
in premitotic G2 cells (7 hr time point) in the nucleus and cytoplasm when CHK1 is largely perinuclear and cytoplasmic. G-4 antibody was used to
detect CHK1.
D: Activation of nuclear AKT results in shift of CHK1 from the nuclear compartment. PTEN was knocked down in U2OS cells by shRNA. Upper panel shows
immunoblot analysis of cells with control and PTEN hairpin. Lower panel shows indirect immunofluorescence of cells with activated nuclear AKT with
concomitant cytosolic CHK1 staining. For comparison, cells infected with the control hairpin RNAi vector are shown. Here, CHK1 is mainly in the nucleus.
G-4 monoclonal antibody was used to detect CHK1.
E: Activation or inhibition of endogenous AKT affects CHK1 localization. U2OS cells were transfected with either control, PTEN, AKT, or PTEN + AKT siRNA.
PTEN downregulation results in activation of nuclear AKT and causes CHK1 to localize to the cytosol (as also shown in D), whereas AKT downregulation
causes CHK1 to remain in the nuclear compartment. After double knockdown of PTEN and AKT, CHK1 can be observed in the nuclei of cells. Here,
CHK1 was detected with DCS-310 monoclonal antibody. Nuclei were stained with DAPI. Images were photographed with a 100× oil objective with a
SPOT camera.CHK1 (Figure 5E). In addition, in the PTEN and AKT double
knockdown, CHK1 was localized to the nucleus. PTEN alone
was knocked down as well to test the reproducibility of CHK1
shift to the cytosol. Again, a striking increase in nuclear
phosphoS473-AKT was detected that was associated with a
shift of CHK1 out of the nucleus.
Serine 280-phosphorylated Chk1 covalently associates
with ubiquitin
In response to DNA damage, ATR and ATM kinases phosphor-
ylate CHK1 (Liu et al., 2000; Sorensen et al., 2003; Zhao and198Piwnica-Worms, 2001). Recently, Jiang et al. demonstrated
that following DNA damage, S345-phosphorylated forms of
CHK1 are predominantly associated with chromatin, and that
this generated a consensus site for 14-3-3 protein binding to
CHK1 that played a role in CHK1 nuclear retention (Jiang et al.,
2003). We were interested in determining whether association
of CHK1 with 14-3-3 proteins may help to explain the compart-
mentalization of CHK1 S280 mutants. However, no binding of
14-3-3σ or ζ proteins to CHK1 could be observed in presence
or absence of DNA damage either by far Western or coimmu-CANCER CELL : FEBRUARY 2005
A R T I C L Enoprecipitation techniques (data not shown). Thus, regulation
of molecular transport of CHK1 by 14-3-3 proteins does not
seem to be a likely scenario in this setting.
We next explored the possibility that monoubiquitination
could regulate the localization of CHK1. Transfection of the
S280E mutant into HEK 293 cells generated a slower migrating
band that was consistent with monoubiquitination (Figure 6A).
To see if ubiquitination was indeed involved in regulation of
Chk1, we cotransfected ubiquitin with chk1, chk1S280A, and
chk1 S280E. Interestingly, more of the same species of slower
migrating chk1 was detected in the S280E lane. In addition,
potentially covalent ubiquitination of wild-type chk1 was evi-
dent in a longer exposure of the immunoblot, but such modifi-
cation of the S280A mutant was barely detectable. This result
was only seen when untagged Chk1 was used in the experi-
ment. N- and C-terminus-tagged Chk1 constructs (both human
and mouse) did not display this property. We wished to confirm
that the shifted product was indeed Chk1 covalently attached
to the ubiquitin polypeptide. For this purpose, HEK 293 and
U2OS cells were cotransfected with pCIN4-mChk1 (WT,
S280A, S280E) and pCMV-His6-ubiquitin and lysed under de-
naturing conditions. Ubiquitin-associated proteins were iso-
lated by incubating the lysates with Ni agarose beads. Analysis
of the SDS-PAGE-resolved eluates showed that Chk1 S280E
was covalently attached to one or two molecules of ubiquitin
(Figure 6B). We wished to investigate whether modification of
the PI3K/AKT pathway might have an effect on ubiquitination
of Chk1. To this end, endogenous PTEN or AKT were knockedFigure 6. Association of phosphomimetic S280E
Chk1 mutant with ubiquitin
A: S280E but not S280A mutant of mouse chk1 is
ubiquitinated when transiently expressed in HEK
293 cells. HEK 293 cells were cotransfected with
mChk1 constructs (WT, S280A, S280E), ubiquitin
(+), empty vector (−), and GFP (as a transfec-
tion control). U indicates transfection with only
GFP. 48 hr posttransfection, cells were lysed and
lysates were analyzed by Western blotting.
B: Covalent binding of Chk1 and ubiquitin. HEK
293 and U2OS cells were transfected with His6-
Ub and wild-type, S280A, or S280E Chk1 mu-
tants. 24 hr later, the cells were lysed under de-
naturing conditions. Ubiquitin-associated pro-
teins were purified on Ni-NTA agarose beads
and eluted. The eluates were fractionated by
SDS-PAGE and analyzed by Western blotting
with pChk1 (S280) antibodies. Input is shown
above.
C: Ubiquitination of Chk1 is PI3K/AKT-depen-
dent. PTEN or AKT was knocked down in U2OS
cells by siRNA technology. The knockdown cells
were transfected with wild-type Chk1 and His6-
Ub. Cellular lysates were analyzed by Western
blotting with indicated antibodies. Downregula-
tion of endogenous PTEN increases Chk1 ubiqui-
tination, whereas downregulation of AKT
decreases it.
D: Association of S280E but not S280A mutant
with ubiquitin affects cytosolic localization of
Chk1. Wild-type, S280A, and S280E Chk1 were
transfected into U2OS cells either alone or with
ubiquitin in the presence of H2B-EGFP plasmid
to monitor transfection. 18 hr later, the cells were fixed and stained with Chk1 (DCS-310) antibody. Only cells expressing weak and moderate levels of GFP
were evaluated. Here, at least 50 cells were counted for each group. Lower panel shows S280A and S280E transfected cells stained with DCS-310 antibody
or DAPI. Note that the dilution of the antibody was such that endogenous CHK1 was not detected.CANCER CELL : FEBRUARY 2005down by siRNA in U2OS cells. Wild-type Chk1 and ubiquitin
were then coexpressed. In the setting of reduced PTEN, the
signal of the upper shifted band was increased when com-
pared to the control. Conversely, downregulation of cellular
AKT resulted in decrease of the signal (Figure 6C).
If ubiquitination were involved in the regulation of Chk1 com-
partmentalization, one would expect to see a difference in sub-
cellular localization of Chk1 mutants in the presence of excess
ubiquitin. For this purpose, Chk1 constructs were expressed in
U2OS cells in the absence or presence of exogenous ubiquitin.
Coexpression of S280A Chk1 with ubiquitin had no effect on
localization of the protein. Here, most transfected Chk1 could
be seen in the nuclear compartment. However, transfection of
ubiquitin shifted the phosphomimetic S280E mutant into the
cytoplasm. Now, 60% of cells display an equal distribution of
Chk1 between nucleus and cytosol, versus 40% in the ab-
sence of excess ubiquitin (Figure 6D).
Alteration of chk1 localization in breast carcinomas
and genetic instability
The results described above demonstrate that activation of the
PI3K-AKT pathway affects CHK1 directly. To test whether loss
of PTEN might influence CHK1 in primary human carcinomas,
immunohistochemical analysis was performed on a panel of
breast carcinomas with antibodies to PTEN, phosphoS473-
AKT, and CHK1. Normal epithelial ducts express more PTEN
than the surrounding stroma and stain weakly in the cytoplasm
with the phospho-AKT (473) antibody (Figures 7A and 7B). Nor-199
A R T I C L EFigure 7. Breast carcinomas with elevated AKT phosphorylation and reduced PTEN protein have altered distribution of CHK1
Staining with antibodies to PTEN, phosphoAKT (S473), and CHK1 were performed in breast carcinomas. Twelve tumor biopsies were examined for CHK1
localization, six with low PTEN and elevated phospho-AKT (S473), and six with normal levels of PTEN and phospho-AKT (S473). Representative examples of
PTEN (A, D, and G), pAKT-473 (B, E, and H), and CHK1 (C, F, and I) staining are shown. Adjacent normal ducts had high PTEN (A), weak phospho-AKT (S473)
(B), and strong nuclear (C) CHK1 staining. Tumor cells with reduced PTEN (D) and increased phospho-AKT (S473) (E) had increased cytoplasmic and
reduced nuclear CHK1 staining (F). Tumor cells with normal levels of PTEN (G) and weak phospho-AKT (H) staining had primarily nuclear CHK1 (I) staining.
Shifted CHK1 staining into the cytoplasm was seen in all six cases with altered PI-3 kinase signaling. Nuclear CHK1 staining was seen in all six cases with
normal PI-3 kinase signaling. χ2 < 0.005. Wide arrows indicate epithelial cells, while narrow arrows indicate stromal cells.mal duct cells had primarily nuclear CHK1, as did the sur-
rounding stroma (Figure 7C). Tumor cells with downregulated
PTEN (Figure 7D) and increased staining for phosphoS473-
AKT (Figure 7E) at the membrane and throughout the cell had
cytoplasmic and nuclear CHK1 at roughly equivalent levels
(Figure 7F). On the other hand, tumors with high PTEN and200low phospho-AKT (S473) expression that was consistent with
normal epithelial cells (Figures 7G and 7H) had largely nuclear
CHK1 (Figure 7I). These data are consistent with AKT kinase
regulating CHK1 localization in human cells lacking PTEN.
CHK1 is a candidate tumor suppressor that preserves geno-
mic integrity during each cell cycle in response to endoge-CANCER CELL : FEBRUARY 2005
A R T I C L Enously and exogenously generated DNA lesions (Bartek and
Lukas, 2003). To see whether loss of PTEN affects genetic sta-
bility, we analyzed a set of primary invasive stage II and stage
III breast carcinomas with normal and low PTEN expression. In
a panel of 109 tumors, lack of PTEN expression was associ-
ated with an increased incidence of aneuploidy in breast carci-
noma (χ2 = 8.34; p < 0.005). While 25 of 77 (32%) tumors with
normal PTEN were diploid, only 2 of 32 (6%) tumors lacking
PTEN had normal ploidy. These results confirm the initial corre-
lation of aneuploidy and loss of PTEN expression that we ob-
served previously in a smaller group of breast tumors (Bose et
al., 2002). Moreover, they suggest that the cytoplasmic local-
ization of CHK1 seen in PTEN-deficient cells is contributing to
their aneuploidy. To confirm the link between PTEN inactivation
and aneuploidy, we examined prostatic intraepithelial neoplasia
(PIN) from eleven Pten+/− mice for aneuploidy (Podsypanina et
al., 1999). We found that 6 of 11 PIN lesions (55%) were aneu-
ploid. Analysis of MES cells after over 30 passages or after
recovery and expansion from 3 Gy of ionizing radiation demon-
strated no evidence of aneuploidy or chromosomal rearrange-
ment due to lack of Pten. These data suggest that the deficit
in checkpoint function is insufficient to cause frank aneuploidy
in the absence of phenotypic selection.
Discussion
CHK1 is in the first line of defense against DNA damage, and
can be activated by a wide variety of stimuli that include ultravi-
olet light, ionizing radiation, and hydroxyurea. By rapidly modu-
lating the level of CDC25A, CHK1 is able to arrest the cell cycle
at the G1/S boundary, S, and G2 phases by altering the kinase
activity of cyclin/cdk complexes E, A, and B, respectively (Fig-
ure 8). In this study, we have shown that PTEN tumor suppres-
sor is an important modulator of CHK1 function. In response
to ionizing radiation, Pten−/− cells had diminished checkpoint
control as early as 1 and 2 hr after treatment (Figure 2), a phe-
notype also observed in MES cells lacking chk1 and RNAi-
mediated knockdown of CHK1 in human cells (Takai et al.,
2000; Zhao et al., 2002). Because of their checkpoint defect,
Pten−/− cells displayed more than a 2-fold increase in the
number of DNA double-strand gaps and breaks 90 min after
treatment with a low dose of ionizing radiation (Figure 2D). We
also have demonstrated that the PI-3 kinase pathway and AKT
were able to stimulate phosphorylation of chk1 serine 280 in
vivo, and that cells lacking Pten had elevated phosphorylated
chk1 at serine 280 (Figure 3). Serine 280 phosphorylation re-
duced the protein’s ability to be phosphorylated at another res-
idue, serine 345, in response to DNA damage (Figure 4E). As a
consequence of reduced Chk1 activity, Pten−/− cells were un-
able to properly regulate cdc25A and the cell cycle (Figures 2
and 4). The influence of the PI-3 kinase pathway on chk1 sig-
naling is demonstrated by the ability of chk1S280A, a mutant
that AKT cannot phosphorylate, to suppress the checkpoint
defect seen in Pten−/− cells and to restore the reduction of
CDC25A after radiation (Figure 4). Since S280A chk1 rescued
the IR-induced phenotype of Pten−/− cells, we looked at sub-
cellular distribution of CHK1 in U2OS cells. We discovered that
CHK1S280A localized mostly to the nuclear compartment,
whereas the phosphomimetic (S280E) mutant could be pre-
dominantly seen in the cytoplasm. In addition, at the G2 phase
of the cell cycle, endogenous CHK1 could be seen departingCANCER CELL : FEBRUARY 2005from the nucleus at the time of peak AKT kinase phosphoryla-
tion at threonine 308 and serine 473 and nuclear localization
(Figure 5). Such reduction in nuclear CHK1 may explain the
increase in Cdc25A protein seen in G2/M phases of the cell
cycle (Bernardi et al., 2000). Reduction of PTEN in U2OS cells
with RNAi led to a marked increase in nuclear foci of phospho-
AKT (S473) and increased cytoplasmic CHK1. Serine 280
phosphorylation appears to be a trigger for monubiquitinatiton
of CHK1, which we have shown to influence cellular localiza-
tion of CHK1 (Figure 6). Overall, this suggests that increased
serine 280 phosphorylation and ubiquitination of CHK1 in
PTEN−/− cells promotes enhanced cytoplasmic localization,
thereby inhibiting its checkpoint function.
Reduced CHK1 function is associated with genomic instabil-
ity and cancer. Mutation of one allele of chk1 stimulates tumor
development in the WNT mouse mammary tumor model (Liu
et al., 2000). In these tumors, no loss of heterozygosity of the
wild-type chk1 allele occurs. Moreover, normal mouse chk1+/−
cells have partial deficits in checkpoint function (Lam et al.,
2004). Since Pten−/− cells also have a reduced amount of chk1
function, we surmise that the chk1 defect seen in Pten−/− cells
contributes to tumor development. In addition, activation of
AKT inhibits p21, p27, and CDC25B, key inhibitors of cyclin/
cdk complexes that facilitate cell cycle arrest in response to
checkpoint activation; moreover, AKT phosphorylates and acti-
vates MDM2 to stimulate p53 destruction (Baldin et al., 2003;
Fujita et al., 2002; Liang et al., 2002; Mayo and Donner, 2001;
Rossig et al., 2001; Shin et al., 2002; Zhou et al., 2001).
The major substrate of CHK1 is CDC25A, which is often over-
expressed in human breast cancer and is able to cooperate
with mutant h-ras to transform mouse embryo fibroblasts
(Cangi et al., 2000; Galaktionov et al., 1995). Overexpression
of CDC25A activates cyclin E/Cdk2 complexes, a complex
shown to induce unscheduled firing of origins of replication
and induction of chromosome instability (Blomberg and Hoff-
mann, 1999; Spruck et al., 1999). Therefore, it seems reason-
able to conclude that the aneuploidy seen in PTEN-deficient
tumors is due at least in part to reduced CHK1 function. Our
finding that CHK1 is shifted into the cytoplasm of primary
breast tumor cells with phosphorylated AKT and reduced
PTEN protein expression supports this hypothesis (Figure 7).
Loss of PTEN leads to increased proliferation and reduced
apoptosis in nontumor cells (Kishimoto et al., 2003). Although
altered proliferation and apoptosis are potent stimuli for tumor
formation, the pace at which spontaneous Pten−/− tumors arise
from Pten−/− normal cells suggests that they have acquired a
new capacity to evolve into tumors (Backman et al., 2004; Ki-
mura et al., 2003; Suzuki et al., 2001; Trotman et al., 2003;
Wang et al., 2003). One explanation for this increased evolu-
tionary capacity is that Pten−/− cells have enhanced genetic
plasticity that allows for the selection of tumor traits. We liken
the modest defect in checkpoint control seen in cells lacking
PTEN to a chink in the armor or a pull in a garment. Such a
weakness is significant, since over many generations, a cell
lacking PTEN has the opportunity to select for further genetic
instability and cooperating mutations that facilitate tumor
growth.
Experimental procedures
Plasmid constructs and gene targeting
The Pten targeting construct containing a resistance cassette was electro-
porated into murine W9.5 embryonic stem cells (Podsypanina et al., 1999).201
A R T I C L EFigure 8. Model of PTEN regulation of DNA damage checkpoints
AKT activation due to the loss of PTEN phosphorylates CHK1 at serine 280
and leads to its monoubiquitination and sequestration from the nu-
cleus. Outside of the nucleus, CHK1 is not able to respond to its activating
kinases ATM and ATR, nor can it phosphorylate substrates such as CDC25A.Recombinants were selected on mitomycin C-treated feeder cells in ES
media (DMEM supplemented with nonessential amino acids, L-Glutamine,
nucleosides, 2-mercaptoethanol, 15% defined fetal bovine serum, and
1000 U/ml of leukemia inhibitory factor [LIF]) and 2 mg/ml of G418 or 0.2
mg/ml hygromycin B for a period of 10 days. Heterozygous mutant cells
were retargeted with a construct bearing the hygromycin-bearing cassette.
Multiple aliquots of cells were frozen and used during the course of the
study to limit variability caused by passage number. For the generation of
mouse chk1 expression vector, mchk1 cDNA (gift of Stephen J. Elledge,
Harvard Medical School) was subcloned into the Not I site of pCIN4 (gift of
Wei Gu, Columbia University). Phosphorylation site mutants were generated
with the Quick Change XL Mutagenesis Kit (Stratagene) using pCIN4-
mChk1 as a template. pCMV6 and pCMV6-myrAKT-HA were provided by
Thomas Franke (Columbia University). pCMV-His6-Ubiquitin vector was a
gift of Richard Baer (Columbia University). The human CHK1 expression
vector was described previously and was the template for the human CHK1
codon 280 mutants (Zhao and Piwnica-Worms, 2001).
Radiation treatment and immunoblotting
Embryonic stem cells were maintained on gelatinized dishes without feeder
cells in ES media supplemented with 1000 U/ml of LIF. 70% confluent ES
cells seeded on 6-well plates were treated with IR from a 137Cs source and
harvested in Laemmli sample buffer at different time points. HEK 293 cells
were transfected by the calcium phosphate method. When pCIN4-mChk1/
pCMV6-myrAKT were used, cells were harvested 24 hr later in Laemmli
sample buffer. Protein extracts were boiled for 5 min and precleared by
centrifugation. Twenty-five micrograms of protein were resolved by SDS-
PAGE on 4%–20% or 8% Tris-Glycine gels. Proteins were transferred to
Immobilon-P membrane (Millipore) and visualized by enhanced chemilumi-
nescence (Pierce). PTEN was detected with polyclonal antibody purchased
from Cascade, and pAKT (S473), pAKT (T308), AKT, pChk1 (S345), pGSK3
(S21/9), pMAPK (T202/Y204) were from Cell Signaling. For determination of
Cdc25A expression, cells were lysed in mammalian cell lysis buffer supple-
mented with 200 nM okadaic acid in place of 1 M microcystin (Zhao and
Piwnica-Worms, 2001). Monoclonal antibodies to CHK1 (G-4) and CDC25A
(F6) were obtained from Santa Cruz Biotechnology. Polyclonal phospho-
histone H3 (S10) antibody was from Upstate Biotechnology. Phospho-Chk1
(S280) antibody was raised in rabbits immunized with the mouse peptide
CRPRAT-pS-GGMS-NH2 covalently attached with cysteine to KLH and af-
finity purified. This antibody does not crossreact with human CHK1.
Growth factor stimulation
For determination of the effect of growth factor stimulation on phosphoryla-
tion of Chk1 protein, mChk1-transfected HEK 293 cells or NIH/3T3 cells
were starved for 24 hr in serum-free DMEM. 100 nM Wortmannin was
added 15 min prior to growth factor addition to inhibit PI3-K. Cells were
pretreated with 10 M LY294002, 50 M PD980059, and 200 nM Rapa-202mycin for 2 hr prior to mitogen addition. Insulin and IGF I (Sigma) were
added to concentration of 100 ng/ml for 15 min.
Phosphatase treatment
Pten nullizygous ES cells were lysed in buffer containing 50 mM Tris-Cl (pH
8.0), 100 mM NaCl, 10 mM MgCl2, 0.5 % Nonidet P-40, 2 mM DTT, 2 mM
PMSF, 10 g of aprotinin per ml, and 5 g of leupeptin per ml. Clarified
lysates containing 150 g of total protein were incubated with 5 U of calf
intestinal phosphatase (NEB) in the absence or presence of 10 mM β-glyc-
erol phosphate and 10 mM NaF at 37°C for 1 hr.
Isolation of ubiquitin-conjugated proteins
60% confluent HEK 293 or U2OS cells in 100 mm dishes were transfected
with 5 g pCIN4-mChk1 (WT, S280A, S280E) and 5 g pCMV-His6-Ub. 24
hr after transfection, cells were lysed under denaturing conditions according
to procedure described by Choudhury et al. (2004).
Checkpoint rescue
60% confluent Pten−/− MES cells growing in gelatinized T75 cm2 flasks
were transfected with 20 g of pCIN4-mChk1 (WT, S280A, S280E) by the
Lifofectamine 2000 method. 48 hr posttransfection, cells were reseeded on
gelatinized T25 cm2 flasks and allowed to attach overnight. Cells were then
irradiated with 10 Gy of ionizing radiation from a 137Cs source at a 1 Gy/
min rate. Nocodazole was added to final concentration of 0.2 g/ ml. Cells
were harvested 24 hr later and were fixed in 2% paraformaldehyde for 10
min and resuspended in 70% ethanol/PBS. Fixed cells were stained with
rabbit phospho histone H3 (S10) antibody (Upstate Biotechnology),
washed, and incubated with Alexa Fluor 488 anti-rabbit IgG (Molecular
Probes). After washing, the positive cells were scored under fluorescent
light. At least 400 nuclei were measured for each time point in triplicate. For
the CDC25A rescue, PTEN wild-type and nullizygous MES were seeded at
60% confluency on gelatinized 6-well plates. Nullizygous cells were
transfected with 0.6 g of either wild-type, S280A, or S280E mChk1 ex-
pression vector. 18 hr posttransfection, the cells were exposed to 10 Gy of
IR from a 137Cs source. After 1 hr, both unirradiated and irradiated cells
were lysed in buffer MCLB. Cell lysates were resolved by SDS-PAGE and
analyzed by WB for CDC25A expression levels.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/2/193/DC1/.
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